| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | N/A | N/A | N/A | N/A | N/A |
| MA10 | N/A | N/A | N/A | N/A | N/A |
| MA20 | N/A | N/A | N/A | N/A | N/A |
| MA50 | N/A | N/A | N/A | N/A | N/A |
| MA100 | N/A | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | N/A | N/A | N/A | N/A | N/A |
| STOCH | N/A | N/A | N/A | N/A | N/A |
| WILL %R | N/A | N/A | N/A | N/A | N/A |
| CCI | N/A | N/A | N/A | N/A | N/A |
|
Monday, February 09, 2026 01:26 PM
Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an ...
|
|
Friday, February 06, 2026 01:39 PM
About This EventAgomAb Therapeutics NV (Nasdaq: AGMB), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with ...
|
|
Friday, February 06, 2026 11:16 AM
Two biotechs making their Nasdaq debuts on Friday witnessed contrasting fortunes. Eyecare firm SpyGlass Pharma (SGP) climbed ~72%, and Belgian biotech Agomab Therapeutics (AGMB) dropped ~13% on their ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 09/02/26 | 14.55 | 16.01 | 14.5103 | 15.61 | 308,680 |
|
|
||||
|
|
||||
|
|